Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:14:30 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:PHAR - PHARMING GROUP NV SPON ADS EACH REP 10 ORD SHS - https://www.pharmanetics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PHAR - Q0.19.24·10.801.010.2536-0.0564-0.54.0403310.27  10.3392  10.253612.61  6.6516:04:15Jun 2415 min RT 2¢

Recent Trades - Last 10 of 33
Time ETExPriceChangeVolume
16:04:15Q10.24-0.071
16:00:01Q10.24-0.075
16:00:01Q10.24-0.074
16:00:01Q10.24-0.0718
15:07:21Q10.24-0.071
15:07:16Q10.2536-0.0564181
14:40:20Q10.33920.02922,000
14:07:49Q10.42630.116350
14:03:41Q10.42150.11151
13:07:29Q10.24-0.0712

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-24 01:00U:PHARNews ReleasePharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
2025-05-08 01:00U:PHARNews ReleasePharming Group reports first quarter 2025 financial results and provides business update
2025-04-25 09:00U:PHARNews ReleasePharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
2025-04-23 03:30U:PHARNews ReleasePharming receives positive recommendation from NICE for Joenja(TM)▼(leniolisib) as a treatment for APDS
2025-03-20 02:00U:PHARNews ReleasePharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation
2025-03-13 02:00U:PHARNews ReleasePharming Group reports fourth quarter and full year 2024 financial results and provides business update
2025-03-04 09:15U:PHARNews ReleasePharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
2025-02-28 02:00U:PHARNews ReleasePharming Group to participate in March investor conference
2025-02-27 02:00U:PHARNews ReleasePharming Group to report fourth quarter and full year 2024 financial results on March 13
2025-02-10 02:00U:PHARNews ReleasePharming Group to participate in February investor conference
2025-01-21 01:00U:PHARNews ReleasePharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer
2024-12-15 13:45U:PHARNews ReleasePharming announces public cash offer to the shareholders of Abliva AB
2024-12-11 01:00U:PHARNews ReleasePharming announces positive topline data in pediatric clinical trial of leniolisib
2024-11-05 02:00U:PHARNews ReleasePharming Group to participate in November investor conference
2024-10-24 01:00U:PHARNews ReleasePharming Group reports third quarter 2024 financial results and provides business update
2024-10-10 02:00U:PHARNews ReleasePharming Group to report third quarter 2024 financial results on October 24
2024-10-10 01:00U:PHARNews ReleasePharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
2024-09-26 01:00U:PHARNews ReleasePharming announces marketing authorization in the U.K. for Joenja(TM) (leniolisib)
2024-09-04 01:00U:PHARNews ReleasePharming Group to participate in September investor conferences
2024-08-01 01:00U:PHARNews ReleasePharming Group reports second quarter and first half 2024 financial results and provides business update